TREMFYA® (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in moderately to severely active Crohn's disease

Data ReadoutpositiveTREMFYAPositive

AI Analysis

Summary

TREMFYA (guselkumab) demonstrated sustained clinical and endoscopic remission through 3 years in patients with moderately to severely active Crohn's disease, supporting the drug's long-term efficacy profile.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

sustained clinical and endoscopic remission through 3 years

Importance:6/10

Sentiment:

0.75

Crohn's diseaseimmunologylong-term dataclinical remissionendoscopic remission

Related Companies

$JNJ

Read the original article

Published by yahoo_finance on October 12, 2026 8:05 PM

Read Original